202 related articles for article (PubMed ID: 30851419)
21. Up-regulation of MBD1 promotes pancreatic cancer cell epithelial-mesenchymal transition and invasion by epigenetic down-regulation of E-cadherin.
Xu J; Zhu W; Xu W; Yao W; Zhang B; Xu Y; Ji S; Liu C; Long J; Ni Q; Yu X
Curr Mol Med; 2013 Mar; 13(3):387-400. PubMed ID: 23331011
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway.
Yao J; Qian C
Med Oncol; 2010 Sep; 27(3):1017-22. PubMed ID: 19816816
[TBL] [Abstract][Full Text] [Related]
23. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity.
Duxbury MS; Ito H; Benoit E; Zinner MJ; Ashley SW; Whang EE
Biochem Biophys Res Commun; 2003 Nov; 311(3):786-92. PubMed ID: 14623342
[TBL] [Abstract][Full Text] [Related]
24. S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway.
Liu Y; Bi T; Liu L; Gao Q; Shen G; Qin L
Naunyn Schmiedebergs Arch Pharmacol; 2019 May; 392(5):615-622. PubMed ID: 30683944
[TBL] [Abstract][Full Text] [Related]
25. MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20.
Yao J; Li Z; Wang X; Xu P; Zhao L; Qian J
Acta Biochim Biophys Sin (Shanghai); 2016 Feb; 48(2):202-8. PubMed ID: 26758190
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway.
Yu C; Chen S; Guo Y; Sun C
Theranostics; 2018; 8(12):3224-3236. PubMed ID: 29930725
[No Abstract] [Full Text] [Related]
27. Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway.
Wu ZH; Lin C; Liu MM; Zhang J; Tao ZH; Hu XC
PLoS One; 2016; 11(12):e0169230. PubMed ID: 28036386
[TBL] [Abstract][Full Text] [Related]
28. Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer.
Gu J; Huang W; Wang X; Zhang J; Tao T; Zheng Y; Liu S; Yang J; Chen ZS; Cai CY; Li J; Wang H; Fan Y
Mol Cancer; 2022 May; 21(1):112. PubMed ID: 35538494
[TBL] [Abstract][Full Text] [Related]
29. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
Pan MR; Hsu MC; Luo CW; Chen LT; Shan YS; Hung WC
Oncotarget; 2016 Sep; 7(38):61136-61151. PubMed ID: 27531902
[TBL] [Abstract][Full Text] [Related]
30. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling.
Zhang Z; Han H; Rong Y; Zhu K; Zhu Z; Tang Z; Xiong C; Tao J
J Exp Clin Cancer Res; 2018 Nov; 37(1):291. PubMed ID: 30486896
[TBL] [Abstract][Full Text] [Related]
32. Knockdown of Ezrin by RNA interference reverses malignant behavior of human pancreatic cancer cells in vitro.
Zhong ZQ; Song MM; He Y; Cheng S; Yuan HS
Asian Pac J Cancer Prev; 2012; 13(8):3781-9. PubMed ID: 23098471
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207.
You L; Wang H; Yang G; Zhao F; Zhang J; Liu Z; Zhang T; Liang Z; Liu C; Zhao Y
Mol Oncol; 2018 Dec; 12(12):2147-2164. PubMed ID: 30341811
[TBL] [Abstract][Full Text] [Related]
34. DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
Liu F; Gore AJ; Wilson JL; Korc M
PLoS One; 2014; 9(1):e84982. PubMed ID: 24409315
[TBL] [Abstract][Full Text] [Related]
35. Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade.
Zhang Z; Duan Q; Zhao H; Liu T; Wu H; Shen Q; Wang C; Yin T
Cancer Lett; 2016 Nov; 382(1):53-63. PubMed ID: 27576197
[TBL] [Abstract][Full Text] [Related]
36. Silencing of TRPM8 inhibits aggressive tumor phenotypes and enhances gemcitabine sensitivity in pancreatic cancer.
Liu J; Hu G; Gong Y; Yu Q; He B; Li W; He Z; Hao W; He Z; Liu Y
Pancreatology; 2018 Dec; 18(8):935-944. PubMed ID: 30316690
[TBL] [Abstract][Full Text] [Related]
37. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
Skrypek N; Vasseur R; Vincent A; Duchêne B; Van Seuningen I; Jonckheere N
Oncotarget; 2015 May; 6(13):10853-67. PubMed ID: 25890497
[TBL] [Abstract][Full Text] [Related]
38. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
39. YAP Inhibition by Nuciferine via AMPK-Mediated Downregulation of HMGCR Sensitizes Pancreatic Cancer Cells to Gemcitabine.
Zhou L; Wang Q; Zhang H; Li Y; Xie S; Xu M
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31627466
[TBL] [Abstract][Full Text] [Related]
40. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
Yokoi K; Fidler IJ
Clin Cancer Res; 2004 Apr; 10(7):2299-306. PubMed ID: 15073105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
